Açıklama

Diltiazem is a potent CYP3A4 inhibitor that significantly increases quetiapine plasma concentrations, raising risk of quetiapine toxicity and QT prolongation.

Mekanizma

Diltiazem inhibits CYP3A4, the primary enzyme responsible for quetiapine metabolism, substantially increasing quetiapine AUC; both drugs also have modest QT-prolonging effects.

Klinik Önemi

Quetiapine levels may increase 2- to 5-fold; sedation, metabolic adverse effects, and QTc prolongation are clinical risks.

Yönetim

Reduce quetiapine dose substantially when adding diltiazem; monitor for excessive sedation, metabolic effects, and ECG changes.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.